天新药业(603235) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for the third quarter was CNY 508,595,002.96, a decrease of 7.02% compared to the same period last year[3] - The total profit for the quarter was CNY 127,055,539.55, reflecting a decline of 27.36% year-over-year[3] - The net profit attributable to shareholders was CNY 104,290,326.83, down 30.15% from the previous year[3] - The net profit after deducting non-recurring gains and losses was CNY 94,675,521.79, a decrease of 31.60% compared to the same period last year[3] - The basic earnings per share for the quarter was CNY 0.24, a decline of 29.41% year-over-year[4] - The net profit for the current period is CNY 460,303,876.13, a decrease of 6.3% compared to CNY 494,482,977.97 in the previous period[20] - Operating profit for the current period is CNY 553,261,896.65, down from CNY 587,740,147.18, reflecting a decline of 5.8%[20] - The company's operating revenue for the first three quarters of 2025 was CNY 1,625,646,618.98, a slight decrease of 0.48% compared to CNY 1,633,432,476.62 in the same period of 2024[33] - The net profit for the first three quarters of 2025 reached CNY 536,096,069.54, compared to CNY 525,646,257.31 in 2024, reflecting an increase of about 1.7%[34] Assets and Liabilities - The total assets at the end of the reporting period were CNY 5,934,285,419.01, an increase of 5.91% from the end of the previous year[4] - The company's total assets as of September 30, 2025, amounted to RMB 5,934,285,419.01, up from RMB 5,603,291,129.63 at the same time last year, reflecting an increase of about 5.9%[18] - Current assets totaled RMB 2,587,926,908.17, a decrease from RMB 2,695,380,695.48 in the previous year, representing a decline of approximately 4.0%[15] - Non-current assets increased to RMB 3,346,358,510.84 from RMB 2,907,910,434.15, marking a growth of around 15.1%[16] - Total liabilities rose to RMB 1,149,043,344.60, compared to RMB 987,405,152.49 in the previous year, indicating an increase of approximately 16.3%[17] - The total liabilities decreased to CNY 543,767,134.91 in 2025 from CNY 704,835,472.43 in 2024, representing a reduction of approximately 22.8%[30] Cash Flow - The cash flow from operating activities for the year-to-date was CNY 490,550,179.09, reflecting an increase of 11.53%[4] - The net cash flow from operating activities is CNY 490,550,179.09, up from CNY 439,852,434.45, indicating an increase of 11.5%[24] - The company's cash inflow from operating activities totaled CNY 1,780,950,222.18 in the first three quarters of 2025, up from CNY 1,593,464,113.43 in 2024, marking an increase of approximately 11.8%[37] - The cash inflow from investment activities is CNY 3,894,940,838.33, compared to CNY 1,008,678,662.63, indicating a substantial increase of 285.5%[25] - The net cash flow from financing activities is CNY -50,707,065.23, an improvement from CNY -278,708,874.74 in the previous period[25] Equity - The equity attributable to shareholders increased to CNY 4,785,242,074.41, up 3.67% from the previous year[4] - The company's total equity as of September 30, 2025, was CNY 4,947,159,833.20, compared to CNY 4,702,011,542.52 at the end of 2024, indicating an increase of about 5.2%[30] Costs and Expenses - Total operating costs for the first three quarters of 2025 were RMB 1,105,745,608.76, compared to RMB 1,058,098,256.39 in 2024, indicating an increase of about 4.5%[19] - Operating costs included RMB 891,446,362.73 in operating expenses, which decreased from RMB 931,582,176.69 in the previous year, showing a reduction of approximately 4.3%[19] - The cost of goods sold for the first three quarters of 2025 was CNY 907,898,585.59, down from CNY 984,594,065.63 in 2024, indicating a reduction of approximately 7.8%[34] - Research and development expenses for the current period are CNY 71,324,408.74, slightly down from CNY 72,715,184.45, a decrease of 1.9%[20] - Research and development expenses for the first three quarters of 2025 were CNY 34,255,601.16, up from CNY 30,744,470.05 in 2024, reflecting an increase of approximately 11.5%[34] Investment Income - The company reported a total investment income of CNY 6,155,700.75, an increase from CNY 3,650,670.48, reflecting a growth of 68.6%[20] - The total cash inflow from investment activities was $3,894,871,946.32, significantly up from $953,658,662.63, indicating a growth of about 308.5%[38] - The net cash flow from investment activities was $202,049,347.01, recovering from a negative cash flow of -$503,404,909.46 in the prior period[38] Market Strategy - The company is focusing on expanding its market presence and enhancing product development, although detailed strategies were not provided in the conference call[19] Exchange Rate Impact - The impact of exchange rate changes on cash and cash equivalents was $3,540,484.46, compared to $38,277,230.60 previously[38]